ELTX Elicio Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1601485 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY22.1%
TTM EPS YoY41.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-315.3%
ROA-105.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets52.4%
Debt / equity0.51x
Current ratio3.43x
Interest coverage-24.46x
Cash quality & payout
Operating cash flow / net income1.03x
Accruals ratio3.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $24.90M | $33.66M |
| SG&A expense | $12.81M | $11.33M |
| Operating income | -$37.71M | -$44.99M |
| Interest expense | $1.13M | $455,000 |
| Pretax income | -$39.57M | -$51.90M |
| Income tax | $0 | $0 |
| Net income | -$39.57M | -$51.90M |
| EBITDA | -$37.51M | -$44.66M |
| EPS (basic) | -2.58 | -4.25 |
| EPS (diluted) | -2.58 | -4.25 |
| Weighted avg. shares (diluted) | 15.31M | 12.20M |
| Balance sheet | ||
| Cash & equivalents | $18.56M | $19.49M |
| Current assets | $19.31M | $20.69M |
| PP&E, net | $295,000 | $483,000 |
| Total assets | $25.86M | $28.18M |
| Current liabilities | $8.11M | $11.52M |
| Short-term debt | $0 | — |
| Long-term debt | $9.41M | $20.03M |
| Total debt | $9.41M | $20.03M |
| Total liabilities | $24.23M | $39.49M |
| Shareholders' equity | $1.64M | -$11.31M |
| Net debt | -$9.16M | $542,000 |
| Shares outstanding | 17.80M | 11.03M |
| Cash flow statement | ||
| Operating cash flow | -$36.95M | -$37.07M |
| Capital expenditure | $16,000 | $87,000 |
| Free cash flow | -$36.97M | -$37.16M |
| Investing cash flow | -$16,000 | -$84,000 |
| Financing cash flow | $36.70M | $42.32M |
| Depreciation & amortization | $204,000 | $321,000 |
| Stock-based compensation | $2.70M | $1.45M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.